Expression of Wilms' tumor 1 (WT1) in oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 42, Issue 2, 2013, Pages 133-139

  Mikami, Toshinari ^a   Hada, Tomohiro ^a   Chosa, Naoyuki ^a   Ishisaki, Akira ^a   Mizuki, Harumi ^a   Takeda, Yasunori ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Oral squamous cell carcinoma; Overexpression; Proliferation; WT1

Indexed keywords

MESSENGER RNA; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL INFILTRATION; CELL PROLIFERATION; CELL STRAIN K 562; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CYTOPLASM; EPITHELIUM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WT1 PROTEINS;

EID: 84873260088     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01182.x     Document Type: Article

References (36)

1. Call KM, Glaser T, Ito CY, et al.Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.
2. Pritchard-Jones K, Fleming S, Davidson D, et al.The candidate Wilms' tumor gene is involved in genitourinary development. Nature 1990; 346: 194-7.
3. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991; 11: 1707-12.
4. Pelletier J, Bruening W, Kashtan CE, et al.Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437-47.
5. Park S, Schalling M, Bernard A, et al.The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993; 4: 415-20.
6. Ramani P, Cowell JK. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours. J Pathol 1996; 179: 162-8.
7. Inoue K, Sugiyama H, Ogawa H, et al.WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-9.
8. Oji Y, Ogawa H, Tamaki H, et al.Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204.
9. Nakatsuka S, Oji Y, Horiuchi T, et al.Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804-14.
10. Oji Y, Inohara H, Nakazawa M, et al.Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 2003; 94: 523-9.
11. Oji Y, Suzuki T, Nakano Y, et al.Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 2004; 95: 822-7.
12. Hashiba T, Izumoto S, Kagawa N, et al.Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo) 2007; 47: 165-70.
13. Wilsher M, Cheerala B. WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 2007; 51: 605-10.
14. Wagner N, Michiels JF, Schedl A, Wagner KD. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 2008; 27: 3662-72.
15. Moriya S, Takiguchi M, Seki N. Expression of the WT1 gene -KTS domain isoforms suppresses the invasive ability of human lung squamous cell carcinoma cells. Int J Oncol 2008; 32: 349-56.
16. Perugorria MJ, Castillo J, Latasa MU, et al.Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res 2009; 69: 1358-67.
17. Langman G, Andrews CL, Weissferdt A. WT1 expression in salivary gland pleomorphic adenomas: a reliable marker of the neoplastic myoepithelium. Mod Pathol 2011; 24: 168-74.
18. Oka Y, Tsuboi A, Murakami M, et al.Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78: 56-61.
19. Oka Y, Tsuboi A, Taguchi T, et al.Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-90.
20. Kawakami M, Oka Y, Tsuboi A, et al.Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85: 426-9.
21. Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-6.
22. Rezvani K, Yong AS, Mielke S, et al.Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-42.
23. Tsuboi A, Oka Y, Osaki T, et al.WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004; 48: 175-84.
24. Morita S, Oka Y, Tsuboi A, et al.A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006; 36: 231-6.
25. Izumoto S, Tsuboi A, Oka Y, et al.Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108: 963-71.
26. Tsuboi A, Oka Y, Nakajima H, et al.Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 2007; 86: 414-7.
27. Iiyama T, Udaka K, Takeda S, et al.WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007; 51: 519-30.
28. Ohta H, Hashii Y, Yoneda A, et al.WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol 2009; 26: 74-83.
29. Takahashi K, Kanazawa H, Akiyama Y, et al.Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue. J Jpn Stomatol Soc 1989; 38: 20-8. (In Japanese).
30. Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinoma. J Oral Pathol Med 1989; 18: 391-5.
31. Miyauchi S, Moroyama T, Sakamoto T, Okamoto T, Takada K. Establishment of human tumor cell line (Ueda-1) derived from squamous cell carcinoma of the floor of the mouth. Jpn J Oral Maxillofac Surg 1985; 31: 1347-51. (In Japanese).
32. Horikoshi M, Kimura Y, Nagura H, Ono T, Ito H. A new human cell line derived from human carcinoma of the gingiva I. Its establishment and morphological studies. Jpn J Oral Maxillofac Surg 1974; 20: 100-6. (In Japanese).
33. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321-34.
34. Wagner N, Panelos J, Massi D, Wagner KD. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 2008; 455: 839-47.
35. Kramer RH, Shen X, Zhou H. Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev 2005; 24: 35-45.
36. Ten Cate AR. Oral Histology Development, Structure, and Function, 5th edn. St. Louis: Mosby, 1998; 345-85.